Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 4Head & Neck 1CNS 1

Conditions

Glioma 12Glioblastoma 6Brain Neoplasms 4Neuroblastoma 3Recurrence 2Parkinson Disease 2Oligodendroglioma 2Neuroendocrine Tumors 2Gliosarcoma 2Ependymoma 2Congenital Hyperinsulinism 2Astrocytoma 2Thyroid cancer, medullary 1Pheochromocytoma 1Parkinsonian Disorders 1Paraganglioma 1Optic Nerve Glioma 1Neoplasms, Neuroepithelial 1Neoplasms 1Lewy Body Disease 1Insulinoma 1Glioma, Subependymal 1Carcinoid Tumor 1

Interventions

tipifarnib 1pentetreotide 1fluorodopa F 18 1cixutumumab 1Trastuzumab 1Salts 1Oxaliplatin 1Octreotide 1Leucovorin 1Floxuridine 1Fentanyl 1Everolimus 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulinoma × fluorodopa F 18 × CNS × Clear all
NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡